While some studies have found that more patients experience extrapyramidal side effects and elevated prolactin in high-dose SGA treatment than with standard doses, others have reported that fewer patients had Parkinsonism on a high-dose SGA and that the rate of withdrawals due to adverse events is also lower in high-dose SGA patients. This evidence concerns the gene PRL and Parkinsonism.